Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis

Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi
Yih-Yuan ChenHorng-Yunn Dou

Abstract

The tuberculosis (TB) pandemic remains a leading cause of human morbidity and mortality, despite widespread use of the only licensed anti-TB vaccine, bacille Calmette-Guerin (BCG). The protective efficacy of BCG in preventing pulmonary TB is highly variable; therefore, an effective new vaccine is urgently required. In the present study, we assessed the ability of novel recombinant BCG vaccine (rBCG) against Mycobacterium tuberculosis by using modern immunological methods. Enzyme-linked immunospot assays demonstrated that the rBCG vaccine, which coexpresses two mycobacterial antigens (Ag85B and CFP10) and human interleukin (IL)-12 (rBCG2) elicits greater interferon-γ (IFN-γ) release in the mouse lung and spleen, compared to the parental BCG. In addition, rBCG2 triggers a Th1-polarized response. Our results also showed that rBCG2 vaccination significantly limits M. tuberculosis H37Rv multiplication in macrophages. The rBCG2 vaccine surprisingly induces significantly higher tumor necrosis factor-α (TNF-α) production by peripheral blood mononuclear cells that were exposed to a nonmycobacterial stimulus, compared to the parental BCG. In this study, we demonstrated that the novel rBCG2 vaccine may be a promising candidate vaccine aga...Continue Reading

References

Nov 1, 1995·American Journal of Respiratory and Critical Care Medicine·F A al-KassimiE A Bamgboye
Jan 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·T F Brewer, G A Colditz
Mar 2, 1994·JAMA : the Journal of the American Medical Association·G A ColditzF Mosteller
Jan 5, 2002·Trends in Microbiology·Pablo J BifaniBarry N Kreiswirth
Sep 21, 2010·Cytometry. Part B, Clinical Cytometry·Erica SalernoElizabeth Raveche
Aug 5, 2011·Immunobiology·Antima GuptaSanjib Bhakta
Nov 1, 2011·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Shiang-Fen HuangMing-Chih Yu
Dec 14, 2011·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·Chih-Wei LinHorng-Yunn Dou
Nov 14, 2013·Ecology and Evolution·Catalina Monzón-ArgüelloSofia Consuegra

❮ Previous
Next ❯

Citations

Jan 27, 2016·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·V K SinghB S Srivastava
May 1, 2021·International Journal of Environmental Research and Public Health·Wei-Ju SuChin-Hui Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.